1. How is it developed?

The DUR criteria development process is shown below. Target drugs are selected based on the clinical use and significance, and their drug label information is reviewed. Additional review of clinical guidelines and further literature review is performed. Based on the collected information and expert opinions, KIDS submit the final conclusion to MFDS.

We also evaluate current use of the target drugs to examine the actual usage in patients and how they are clinically significant especially in terms of adverse drug reactions. Korea Adverse Event Reporting System (KAERS) database and other claims data from various sources are used for analysis.

Steps of DUR information review

KIDS evaluate and develop DUR criteria both regularly and in as-needed basis. Regular evaluation is done for frequently prescribed drugs, drugs with safety issues, and drugs requiring interventions. This is evaluated and updated regularly. Special evaluation is done when clinicians submit suggestions regarding DUR criteria change or further examination of previous criteria.

2. Current status of DUR information (as of 2024.08.09.)